Darzalex (Daratumumab) for Myeloma

Overview
Darzalex is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating multiple myeloma in people who have tried other therapies or who are ineligible for autologous stem cell transplant. Darzalex is often combined with other drugs such as Velcade, Pomalyst, or Revlimid, along with a corticosteroid. Darzalex may also be referred to by its drug name, daratumumab.

Darzalex is an anti-cancer drug. Darzalex is a member of a class of drugs called biologics. Darzalex is a monoclonal antibody designed to attach to myeloma cells. Darzalex is believed to work by killing myeloma cells directly and by helping the immune system recognize and attack myeloma cells.

How do I take it?
Darzalex is administered as an intravenous infusion.

Side effects
The FDA-approved label for Darzalex lists common side effects including infusion site reactions, low blood cell counts, fatigue, dizziness, fever, chills, cough, cold or flu symptoms, nausea, vomiting, diarrhea, constipation, back pain, joint pain, muscle spasms, peripheral neuropathy (pain, tingling, or numbness in the extremities), and swelling in the extremities.

Rare but serious side effects listed for Darzalex include severe infusion site reactions and low blood cell counts.

For more details about this treatment, visit:

Darzalex — Janssen
https://www.darzalex.com

Drug Therapy for Multiple Myeloma — American Cancer Society
https://www.cancer.org/cancer/multiple-myeloma/...